These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 31738426

  • 1. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A.
    Ann Oncol; 2019 Nov 01; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
    [Abstract] [Full Text] [Related]

  • 2. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A.
    Ann Oncol; 2019 Nov 01; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [Abstract] [Full Text] [Related]

  • 3. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators.
    Lancet Oncol; 2020 Feb 01; 21(2):271-282. PubMed ID: 31838007
    [Abstract] [Full Text] [Related]

  • 4. Evolving role of entrectinib in treatment of NTRK-positive tumors.
    Chawla N, Bui NQ, Seetharam M.
    Future Oncol; 2021 Aug 01; 17(22):2835-2846. PubMed ID: 33896226
    [Abstract] [Full Text] [Related]

  • 5. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E, Scaltriti M, Drilon A.
    Nat Rev Clin Oncol; 2018 Dec 01; 15(12):731-747. PubMed ID: 30333516
    [Abstract] [Full Text] [Related]

  • 6. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
    Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, Ventura A, Drilon A, Cocco E.
    Br J Cancer; 2024 Aug 01; 131(3):601-610. PubMed ID: 38902532
    [Abstract] [Full Text] [Related]

  • 7. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS.
    Lancet Oncol; 2018 May 01; 19(5):705-714. PubMed ID: 29606586
    [Abstract] [Full Text] [Related]

  • 8. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
    Kim EE, Park CK, Kim SK, Phi JH, Paek SH, Choi JY, Kang HJ, Lee JH, Won JK, Yun H, Park SH.
    Acta Neuropathol Commun; 2024 Jul 16; 12(1):118. PubMed ID: 39014476
    [Abstract] [Full Text] [Related]

  • 9. TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.
    Harada G, Drilon A.
    Cancer Genet; 2022 Jun 16; 264-265():33-39. PubMed ID: 35334340
    [Abstract] [Full Text] [Related]

  • 10. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N, McDermott R.
    Expert Rev Clin Pharmacol; 2019 Oct 16; 12(10):931-939. PubMed ID: 31469968
    [Abstract] [Full Text] [Related]

  • 11. Tropomyosin receptor kinase inhibitors in the management of sarcomas.
    Wilding CP, Loong HH, Huang PH, Jones RL.
    Curr Opin Oncol; 2020 Jul 16; 32(4):307-313. PubMed ID: 32541318
    [Abstract] [Full Text] [Related]

  • 12. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F, Rudzinski ER, Sepulveda AR.
    J Clin Pathol; 2019 Jul 16; 72(7):460-467. PubMed ID: 31072837
    [Abstract] [Full Text] [Related]

  • 13. Larotrectinib for the treatment of TRK fusion solid tumors.
    Laetsch TW, Hawkins DS.
    Expert Rev Anticancer Ther; 2019 Jan 16; 19(1):1-10. PubMed ID: 30350734
    [Abstract] [Full Text] [Related]

  • 14. Targeting TRK family proteins in cancer.
    Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS.
    Pharmacol Ther; 2017 May 16; 173():58-66. PubMed ID: 28174090
    [Abstract] [Full Text] [Related]

  • 15. NTRK fusions in lung cancer: From biology to therapy.
    Harada G, Santini FC, Wilhelm C, Drilon A.
    Lung Cancer; 2021 Nov 16; 161():108-113. PubMed ID: 34563714
    [Abstract] [Full Text] [Related]

  • 16. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
    Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, Aisner DL, Li Y, Stephens PJ, Morosini D, Tuch BB, Fernandes M, Nanda N, Low JA.
    Cancer Discov; 2015 Oct 16; 5(10):1049-57. PubMed ID: 26216294
    [Abstract] [Full Text] [Related]

  • 17. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
    Rohrberg KS, Lassen U.
    Drugs; 2021 Mar 16; 81(4):445-452. PubMed ID: 33400240
    [Abstract] [Full Text] [Related]

  • 18. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
    Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, Nieva JJ, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, Subramanian J, Sashital D, Stinchcombe T, Kiedrowski L, Price K, Gandara DR.
    Br J Cancer; 2022 Feb 16; 126(3):514-520. PubMed ID: 34480094
    [Abstract] [Full Text] [Related]

  • 19. How I treat NTRK gene fusion-positive cancers.
    Lassen U.
    ESMO Open; 2019 Feb 16; 4(Suppl 2):e000612. PubMed ID: 31803506
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers.
    Hong DS, Drilon A, Wirth LJ.
    Clin Adv Hematol Oncol; 2024 Feb 16; 22 Suppl 5(6):1-20. PubMed ID: 38953725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.